最新ニュース Invivyd (NASDAQ:IVVD) 株価情報

Invivyd

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Invivyd Inc

Citigroup analyst Paul Lejuez maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Neutral and lowers the price target from $72 to $57.

News

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Nike, Lowers Price Target to $57

An Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) analyst says results will be "better-than-feared" when the technology giant reports second-quarter<a href="https://www.benzinga.com/earnings"> financial results Thursday.</a>
The Apple Analyst: JPMorgan analyst Samik Chatterjee maintained an Overweight rating on Apple with a $245 price target.
The Analyst Takeaways: Chatterjee said in a new investor note that fears of demand disruption and cost headwinds from tariffs on China could weigh on Apple stock ahead of quarterly earnings.
Read Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44961882/iphone-resecue-apple-tariff-worries"> Apple Stock Can Brush Off Tariff Concerns, Analyst Says Q2 Beat Coming Thanks To iPhone Demand</a>
"We are positive on AAPL shares with a near-term view into a positive set up into earnings with the likelihood of better-than-feared outcomes in relation to both revenues and gross margins," Chatterjee said.
The analyst expects "modest pull-forward" in demand thanks to consumer upgrades and channel inventory fill.
Chatterjee said revenue will likely be stronger than expected in the second quarter, and momentum could carry over into the third quarter. 
Expect Apple to guide to low-single to mid-single-digit revenue growth for the third quarter, he said. The analyst sees lower downside risk for the full financial year than investors expect. Tariffs remain a "significant uncertainty," but Apple's history could overcome the weakness.
"The resilience of revenue and earnings estimates as well as a proven track record of earnings protection in downturns remains key to investors still looking at AAPL shares favorably despite the uncertainty."
Chatterjee said the company's earnings and guidance could show Apple's resilience in the face of tariff worries and the macro environment.
Services growth, AI opportunities and the new iPhone 17 cycle are catalysts that provide "limited downside risks over the medium term," Chatterjee said.
AAPL Price Action: Apple stock is down 0.6% to $207.96 on Monday versus a 52-week trading range of $169.11 to $260.09. Apple stock is down 14.7% year-to-date in 2025, while shares remain up 19.9% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44366890/apple-stock-faces-pressure-from-declining-iphone-revenue-could-companys-first-foldable-smartphone-in-2026-reverse-course">Apple Stock Faces Pressure From Declining iPhone Revenue: Could Company&#8217;s First Foldable Smartphone In 2026 Reverse Course?</a></li>
</ul>
Image: Shutterstock

Analyst Color

Previews

Reiteration

Tech

Trading Ideas

AAPL

Apple Q2 Will Be 'Better-Than-Feared': Analyst Says iPhone Company Has 'Proven Track Record'

WIIM

MYNZ

Mainz Biomed shares are trading higher after the company announced its Q1 corporate update and path to FDA premarket approval.

Piper Sandler analyst Nathan Race maintains First Merchants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRME#NASDAQ">FRME</a>) with a Overweight and lowers the price target from $55 to $49.

FRME

Piper Sandler Maintains Overweight on First Merchants, Lowers Price Target to $49

Piper Sandler analyst Nathan Race maintains First Business Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>) with a Overweight and raises the price target from $57 to $58.

FBIZ

Piper Sandler Maintains Overweight on First Business Finl Servs, Raises Price Target to $58

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 200 points on Monday.
The Dow traded down 0.27% to 40,004.11 while the NASDAQ fell 1.19% to 17,175.43. The S&amp;P 500 also fell, dropping, 0.72% to 5,485.36.
Check This Out: <a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a>
Leading and Lagging Sectors Financial shares jumped by 0.6% on Monday.
In trading on Monday, information technology fell by 0.6%.
Top Headline
Roper Technologies, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) reported better-than-expected earnings for its first quarter and raised its forecast.
The company posted first-quarter adjusted earnings per share of $4.78, beating the street view of $4.74. Quarterly sales of $1.88 billion outpaced the analyst consensus estimate of $1.82 billion.
Roper Technologies expects fiscal 2025 adjusted earnings per share of $19.80-$20.05 (compared to a previous outlook of $19.75-$20.00), versus the $19.92 estimate. It increased its full-year total revenue growth outlook to ~12% or $7.88 billion (compared to a previous outlook of 10%+ or $7.74 billion) and an analyst estimate of $7.74 billion. It reiterated organic revenue growth of +6-7%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) shares shot up 46% to $2.2999. Galmed signed a term sheet for the development of novel semaglutide sublingual formulation.</li>
<li>Shares of CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>)got a boost, surging 31% to $29.21 after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting.</li>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares were also up, gaining 42% to $1.15 after the company signed a secured credit facility with Yorkville Advisors. The company also reported preliminary first-quarter results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares dropped 28% to $0.0935 after the company announced it approved a plan to implement a workforce reduction.</li>
<li>Shares of Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) were down 15% to $16.86.</li>
<li>Protara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) was down, falling 19% to $3.4899 as the company announced interim results highlighting durable clinical responses with TARA-002 In high-risk NMIBC.</li>
</ul>
Commodities In commodity news, oil traded down 2% to $61.78 while gold traded up 0.6% at $3,316.80.
Silver traded down 0.5% to $32.845 on Monday, while copper rose 0.1% to $4.90.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.74%, Germany's DAX 40 gained 0.67% and France's CAC 40 gained 0.87%. Spain's IBEX 35 Index gained 0.81%, while London's FTSE 100 rose 0.30%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 surging 0.38%, China's Shanghai Composite falling 0.20%, Hong Kong's Hang Seng Index falling 0.04% and India's BSE Sensex gaining 1.27%.
Economics
The Dallas Fed manufacturing index will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45037469/stride-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday">Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For</a> Monday.</li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

CGON

GLMD

GRPN

PLUG

SPRB

TARA

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook

Piper Sandler analyst Justin Crowley maintains Eagle Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGBN#NASDAQ">EGBN</a>) with a Neutral and lowers the price target from $25 to $21.

EGBN

Piper Sandler Maintains Neutral on Eagle Bancorp, Lowers Price Target to $21

Piper Sandler analyst Matthew Clark maintains CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>) with a Overweight and lowers the price target from $25 to $24.

CVBF

Piper Sandler Maintains Overweight on CVB Financial, Lowers Price Target to $24

Piper Sandler analyst Matthew Clark maintains Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) with a Overweight and lowers the price target from $32 to $30.

COLB

Piper Sandler Maintains Overweight on Columbia Banking System, Lowers Price Target to $30

Protara Therapeutics shares are trading lower. The company announced updated results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002

Citigroup analyst Paul Lejuez maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Neutral and lowers the price target from $330 to $275.

LULU

Citigroup Maintains Neutral on Lululemon Athletica, Lowers Price Target to $275

Piper Sandler analyst Justin Crowley maintains Civista Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIVB#NASDAQ">CIVB</a>) with a Neutral and raises the price target from $23 to $24.

CIVB

Piper Sandler Maintains Neutral on Civista Bancshares, Raises Price Target to $24

Citigroup analyst Paul Lejuez maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Buy and lowers the price target from $215 to $150.

DECK

Citigroup Maintains Buy on Deckers Outdoor, Lowers Price Target to $150

Piper Sandler analyst Thomas Champion maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Overweight and lowers the price target from $90 to $80.

Piper Sandler Maintains Overweight on Zillow Gr, Lowers Price Target to $80

Piper Sandler analyst Thomas Champion maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Neutral and lowers the price target from $5120 to $5077.

BKNG

Piper Sandler Maintains Neutral on Booking Holdings, Lowers Price Target to $5077

ONON

On Holding shares are trading higher after Citigroup upgraded the stock from Neutral to Buy, while cutting its price target from $65 to $60.

Citigroup analyst Paul Lejuez maintains Amer Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) with a Buy and lowers the price target from $36 to $30.

Citigroup Maintains Buy on Amer Sports, Lowers Price Target to $30

Piper Sandler analyst Thomas Champion maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and lowers the price target from $210 to $174.

EXPE

Piper Sandler Maintains Neutral on Expedia Group, Lowers Price Target to $174

Live On CNBC, Steve Weiss Announces Bought More UnitedHealth Group

Citigroup analyst Alicia Yap maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Buy and lowers the price target from $56 to $51.

Citigroup Maintains Buy on JD.com, Lowers Price Target to $51

Press Releases

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges – More Stocks Inside

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Health Care

General

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Management

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Financing

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

EVAX

GSIT

IVVD

KAPA

PRSO

QNTM

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Agenus

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Biomea Fusion

Climb Bio

Caribou Biosciences

CervoMed

Elicio Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

I-MAB

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Seres Therapeutics

MediciNova

Sutro Biopharma

Instil Bio

Tenaya Therapeutics

Vigil Neuroscience

XBiotech

Exicure

HC Wainwright & Co.

D. Boral Capital

Morgan Stanley

EF Hutton

Guggenheim

Comments

Invivyd

ニュース

最新ニュース Invivyd (NASDAQ:IVVD) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル